clinical trial · NCT04125472
Expanded Access Protocol to Provide Lumasiran to Patients With Primary Hyperoxaluria Type 1
Primary HyperoxaluriaLumasiran
brief summary
The purpose of this study is to provide expanded access to lumasiran for adults and pediatric patients with Primary Hyperoxaluria Type 1 (PH1),
started
—
primary completion
—
completion
—
last updated
Feb 16, 2024
detailed description
Choosing to participate in an expanded access program is an important personal decision. Talk with your doctor and family members or friends about deciding to join a research study. To learn more about this study, please have your doctor contact the study research staff using the Contacts provided. For general information, see the link provided in More Information.
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol